Federal Register / Vol. 65, No. 28 / Thursday, February 10, 2000 / Notices 6635

823(a) and determined that the

registration of Irix Pharmaceuticals, Inc.

to manufacture methylphenidate is

consistent with the public interest at

this time. DEA has investigated the firm

on a regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security system, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: February 4, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–3145 Filed 2–9–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated October 8, 1999, and

published in the Federal Register on

October 18, 1999, (64 FR 56227),

LifePoint, Inc., 10410 Trademark Street,

Rancho Cucamonga, California 91730,

which has been changed to 10400

Trademark Street, Rancho Cucamonga,

California 91730, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ..... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Phencyclidine (7471) .................... II

Benzoylecgonine (9180) ............... II

Morphine (9300) ........................... II

The firms plans to use gram quantities

of the listed controlled substances to

manufacture drug abuse test kits.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of LifePoint, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated the firm on a regular basis

to ensure that the company’s continued

registration is consistent with the public

interest. These investigations have

included inspection and testing of the

company’s physical security systems,

audits of the company’s records,

verification of the company’s

compliance with state and local laws,

and a review of the company’s

background and history. Therefore,

pursuant to 21 U.S.C. 823 and 28 CFR

0.100 and 0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: January 27, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–3146 Filed 2–9–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA # 186I]

Controlled Substances: Established

Initial Aggregate Production Quotas

for 2000

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Notice of aggregate production

quotas for 2000.

SUMMARY: This notice establishes initial

2000 aggregate production quotas for

controlled substances in Schedules I

and II of the Controlled Substances Act

(CSA). This notice replaces and

supersedes the final order dated

December 21, 1999 and published in the

Federal Register (64 FR 72686). Since

the aggregate production quotas listed

herein are the same as those published

in 64 FR 72686, except as noted below,

this will not effect individual

manufacturing quotas or procurement

quotas previously issued by DEA.

Further, this notice corrects two errors

in the notice published in 64 FR 72686

as follows: the aggregate production

quota of 2 grams for the Schedule I

substance codeine-N-oxide was

inadvertantly deleted from the notice;

and, the aggregate production quotas for

hydrocodone (for conversion) and

hydromorphone were inadvertantly

listed twice. These two corrections are

incorporated into the list of aggregate

production quotas below.

EFFECTIVE DATE: February 10, 2000.

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the CSA (21 U.S.C. 826) requires

that the Attorney General establish

aggregate production quotas for each

basic class of controlled substance listed

in Schedules I and II. This

responsibility has been delegated to the

Administrator of the DEA by § 0.100 of

Title 28 of the Code of Federal

Regulations. The Administrator, in turn,

has redelegated this function to the

Deputy Administrator, pursuant to

§ 0.104 of Title 28 of the Code of Federal

Regulations.

The 2000 aggregate production quotas

represent those quantities of controlled

substances that may be produced in the

United States in 2000 to provide

adequate supplies of each substance for:

The estimated medical, scientific,

research and industrial needs of the

United States; lawful export

requirements; and the establishment

and maintenance of reserve stocks (21

U.S.C. 826(a) and 21 CFR 1303.11).

These quotas do not include imports of

controlled substances for use in

industrial processes.

On October 21, 1999, a notice of the

proposed initial 2000 aggregate

production quotas for certain controlled

substances in Schedules I and II was

published in the Federal Register (64

FR 56809). All interested persons were

invited to comment on or object to these

proposed aggregate production quotas

on or before November 22, 1999.

Six companies commented on a total

of 16 Schedules I and II controlled

substances within the published

comment period. The companies

commented that the proposed aggregate

production quotas for alfentanial,

amphetamine, diphenoxylate, fentanyl,

hydromorphone, levorphanol,

meperidine, levo-desoxyephedrine,

methamphetamine (for sale),

methamphetamine (for conversion),

methylphenidate, noroxymorphone (for

conversion), oxycodone (for sale),

oxycodone (for conversion), sufentanil

and thebaine were insufficient to

provide for the estimated medical,

scientific, research and industrial needs

of the United States, for export

requirements and for the establishment

and maintenance of reserve stocks.

In addition, one comment was

received after the published comment